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Kaposi’s sarcoma-associated herpesvirus (KSHV) open reading frame 50 (ORF50) encodes a viral tran-
scriptional activator which stimulates the transcription of viral early and late genes of KSHV. Here we show
that ORF50 represses transcriptional activity of p53 and p53-induced apoptosis through interaction with
CREB binding protein (CBP). This inhibitory effect of ORF50 on the transcriptional activity of p53 was
relieved by the addition of CBP. ORF50 mutants, which are defective in interaction with CBP, lost the
inhibitory effects on p53. Our data provide a framework for delineating the regulatory mechanisms used by
KSHV to modulate cellular transcription and the cell cycle.
Kaposi’s sarcoma-associated herpesvirus (KSHV) has been
identified as an important pathogen in Kaposi’s sarcoma (2, 4).
DNA sequences of KSHV have been determined, and its in
vitro culture system was recently developed (15, 16). The most
important step in the KSHV life cycle may be the switch from
latency to lytic replication. Upon chemical induction, KSHV
produces immediate-early viral transcripts. These transcripts
encode viral transcriptional activator proteins, such as open
reading frame 50 (ORF50) and K8, which are necessary to
induce the lytic phase (18). ORF50 is a homolog of the Ep-
stein-Barr virus (EBV) immediate-early gene product Rta.
ORF50 is a viral transcriptional activator, which activates the
early and late genes in the KSHV lytic cycle (11, 12, 17). It has
been reported that ORF50 activates the lytic cycle of KSHV
and is expressed earlier than K8, a homolog of the EBV Zta
protein, which induces the lytic cycle of EBV (12, 17). Previ-
ously we reported that ORF50 binds to the C/H3 domain and
the carboxyl-terminal transcriptional activation domain of
CREB binding protein (CBP), while CBP binds to the amino-
terminal basic domain and the carboxyl-terminal transactiva-
tion domain. The LXXLL motif of ORF50 and both of these
domains are necessary for the complete activity of binding to
CBP in vivo (7). Many viral proteins modify the transactivation
function of cellular transcription factors through a CBP-re-
lated mechanism. CBP-related transcriptional activation of c-
Jun and CREB is inhibited by the adenovirus E1A (9, 13). The
E6 protein from human papillomavirus inhibits the intrinsic
transcriptional activation activity of CBP, and it decreases the
activity of the p300/CBP coactivator complex to activate p53-
and NF-kB-responsive promoter elements (14). The Tax pro-
tein from human T-cell leukemia virus type 1 not only in-
creases the binding of CREB to the viral CREB-responsive
element but also recruits CBP to the site of transcription (8).
These results show that the viral proteins modulate the activ-
ities of cellular transcription factors that are important for cell
cycle progression, cellular differentiation, and cell proliferation
through the interaction of viral proteins with p300/CBP.
Because p53 uses CBP as a transcription cofactor and binds
to the carboxyl-terminal transactivation domain of CBP (6, 10),
we investigated whether or not ORF50 could inhibit transcrip-
tional activation by p53 by using transient-transfection assays.
PG13-Luc, WWP-Luc, MDM2-Luc, and the p53 expression
vectors were provided by B. Vogelstein and R. Roeder. ORF50
and the ORF50 deletion mutants were subcloned into pME18S
(the EcoRI and XhoI site; a kind gift of W. M. Yang) by using
PCR. Transfection assays were performed in 293T cells by the
standard calcium precipitation method. In all assays, the lucif-
erase activity derived from the reporter plasmids was deter-
mined after being normalized to b-galactosidase activity from
a cotransfected RSV-bgal control plasmid. All experiments
were performed at least in triplicate. One microgram of re-
porter plasmid and 20 ng of RSV-bgal control plasmid were
transfected into 293T cells, and the amounts of the expression
plasmids are indicated in the figures. The total amount of each
expression vector was kept constant by adding an empty ex-
pression plasmid. Figure 1A shows the various mutants of
ORF50. In our previous work (7) we showed that ORF50
should have both an N-terminal region (amino acids 1 to 300)
and a C-terminal LXXLL region for complete interacting ac-
tivity with CBP in vivo. ORF50 binds to CBP, while N589,
C301-691, and LXXAA mutants, which each had one of the
CBP binding regions deleted, lost their binding activity to CBP
in vivo. Meanwhile, N599 shows a relatively reduced binding
activity to CBP compared to that of wild-type ORF50. ORF50
inhibited p53-mediated activation of PG13-Luc, MDM2-Luc,
and WWP-Luc in 293T cells (Fig. 1B). This inhibitory effect of
ORF50 was observed in C33A and SAOS2 cells as well (data
not shown). C301-691, N589, and LXXAA mutants did not
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show any inhibitory effects on p53-driven transcriptional acti-
vation. N599 showed a moderate inhibitory effect on p53-
driven transcriptional activation compared to that of wild-type
ORF50. As shown in Fig. 1B, the expressed amounts of the
mutants were no smaller than the amount of ORF50, although
some variations were detected. Since these ORF50 mutants do
not repress the p53-driven transcriptional activation activity
that wild-type ORF50 did, we conclude that the decreased
inhibitory effects of C301-691, N589, and LXXAA were not
due to the smaller amount of expression of the mutated forms.
For the following reasons, we hypothesized that this inhibi-
tory effect was mostly derived from the inhibition of interaction
between p53 and CBP by ORF50, although we still cannot rule
out the possibility of the direct interaction between p53 and
ORF50. ORF50 mutants C301-691, N589, and LXXAA, which
do not bind to CBP, do not show any p53 inhibitory effect,
while ORF50 inhibits p53 activity (Fig. 1B). N599, which has a
reduced binding activity to CBP, still shows the inhibitory ef-
fects on p53-driven transcriptional activation, although this
inhibitory effect was reduced compared to that of wild-type
ORF50. Using various techniques, such as the mammalian
two-hybrid technique and immunoprecipitation, we did not
detect any direct interaction between ORF50 and p53 from the
cellular extract cotransfected with the expression vectors con-
taining ORF50 and p53 genes in our conditions (data not
shown). To further clarify this result, we performed a compar-
ative analyses (transient-transfection and luciferase assays) of
ORF50 and adenovirus E1A, which are known to repress p53
transcriptional activity mediated by CBP (6, 10). Indeed,
ORF50 inhibited the p53-responsive promoters and the inhib-
itory effects were relieved by the addition of CBP, as was
observed when adenovirus E1A was used as a control (Fig.
2A). The inhibitory effect of N599 was slightly relieved by the
addition of CBP. We thought that this weak relief was related
to the weak binding activity of N599 to CBP. The addition of
CBP did not affect the p53-driven transcriptional activation
activity. This is not surprising, because an earlier group found
that a large amount of CBP was necessary to increase the
p53-driven transcriptional activation activity (6). They used an
amount of CBP a thousand times greater than that of p53 to
observe an approximately sixfold activation of p53-induced
activation. We used an equal amount of CBP to p53, so it is
hard to see p53-driven transcriptional activation by the addi-
tion of CBP. In conclusion, the inhibitory effect of ORF50 on
FIG. 2. ORF50 repressed transactivation of p53 through interac-
tion with CBP. (A) To determine whether inhibition by ORF50 could
be relieved by the addition of CBP, the fold activation in luciferase
activity was determined. (B) ORF50 inhibited the transcriptional ac-
tivation of Gal4/p53. (C) ORF50 repressed p53 transactivation, while
the ORF50 mutant LXXAA, which does not bind to CBP, could not
inhibit p53 transactivation in the B-cell lymphoma cell line, BJAB.
FIG. 1. ORF50 represses p53-induced transactivation. (A) The do-
mains within ORF50 and the mutated forms of ORF50 are shown.
ORF50 contains the basic domain, the leucine zipper motif (LZ), and
the transcriptional activation domain (TAD). The LXXLL motif,
which interacts with CBP, is located between amino acids 593 and 597
of ORF50. (B) The fold activation of the luciferase activity was deter-
mined with the p53-responsive reporters, and the following reporters
were used: PG13-Luc (synthetic p53 binding site), MDM2-Luc (the
promoter of MDM2 protein), and WWP-Luc (the promoter of p21).
All of the ORF50 mutants were introduced into pME18S, a mamma-
lian expression vector containing the SRa promoter and a Flag tag.
293T cells were transfected with the indicated vectors, and extracts
were analyzed by blotting with anti-Flag antibody (upper right panel).
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p53-driven transcriptional activation was relieved by the addi-
tion of CBP, and this relief was not derived from the increase
of p53 transcriptional activation by CBP.
To prove that the inhibitory effect of ORF50 was not derived
from the modulation of the DNA binding activity of p53, we
determined the luciferase activity of p53 fused to the Gal4
DNA binding domain (Gal4/p53) (Fig. 2B). Gal4/p53-activated
transcription of Gal4-Luc was greater than that of the Gal4
DNA binding domain alone by about 95-fold. This activity was
repressed to 20-fold of that of the Gal4 binding domain alone
in the presence of ORF50. The LXXAA mutant could not
repress this activity of Gal4/p53 at all. Cotransfection of
ORF50 expression vectors reduced transcriptional activation
by p53 to 0.1-fold in the B-cell lymphoma BJAB cell line (Fig.
2C). In contrast, increasing concentrations of LXXAA did not
affect the transcriptional activity of p53 in the BJAB cells.
To determine the biological effects of ORF50 on p53 func-
tion, we examined ORF50 regulation of p53-induced apopto-
sis. Overexpression of p53 induces apoptosis in SAOS2 cells.
ORF50 and the mutated forms alone did not show any cyto-
toxic effect when transfected into these cells (Fig. 3A and B).
SAOS2 cells (106) were cotransfected with pCMV-p53 (1 mg)
and pcDNA3/ORF50 (3 mg), and after 48 h of incubation the
cells were fixed with 70% ethanol on ice for 1 h. Cells were
stained with propidium iodide (50 mg/ml), and the hypoploid
cell fraction was analyzed by a fluorescence-activated cell
sorter (FacsCalibur; Becton-Dickinson, Mountain View, Cal-
if.). The p53-transfected cells showed altered DNA contents,
which is indicative of apoptosis (Fig. 3A). ORF50 severely
repressed p53-induced apoptosis when cotransfected with p53,
while N589 and LXXAA mutants did not show any inhibitory
effect. N599 showed a moderate inhibitory effect on the p53-
induced apoptosis, and these results showed a pattern similar
to that of the result of effects on p53-driven transcriptional
activation. These observations were confirmed by counting the
apoptotic cells cotransfected with green fluorescent protein
(GFP). SAOS2 cells (106) were transfected with pEGFP-C1
(0.5 mg) and with a variety of vector constructs. Forty-two
hours after transfection the cells were fixed with a 4% form-
aldehyde–phosphate-buffered saline solution for 30 min, and
then they were stained with 10 mg of 49,69-diamidino-2-phe-
nylindole (DAPI)/ml for 10 min. The level of apoptosis was
determined by using a fluorescent microscope to count DAPI-
stained condensed nuclei and then dividing this number by the
number of GFP-expressing cells. Transfection of cells with p53
dramatically increased the apoptotic cell population compared
to that of GFP-transfected cells (Fig. 3B). The apoptotic pop-
ulation was reduced to the negative control level when it was
cotransfected with wild-type ORF50 but not with N589 or
LXXAA. N599 shows a reduced inhibitory effect on p53-in-
duced apoptosis.
ORF50 stimulates the viral promoters to promote the lytic
phase of KSHV (11). In contrast, ORF50 represses p53-driven
transcriptional activation through a CBP-related mechanism.
KSHV encodes many cellular homologs related to cell prolif-
eration and survival. ORF72/v-cyclin inactivates the retinoblas-
toma protein (3). KSHV latency-associated nuclear antigen
binds to p53 and inhibits p53-induced apoptosis (5). We dem-
onstrated here that ORF50 inactivated p53-induced transcrip-
tional activation and apoptosis. In fact, many viral transactiva-
tors, such as E1A and Tax, inhibit p53-induced apoptosis as
well (1, 6, 10). Our results suggest that ORF50 not only acts as
a transcriptional activator to induce the lytic phase of KSHV
but also acts as a regulator for the cell cycle to sustain viral
persistence. ORF50 can either activate or repress cellular tran-
scription factors to benefit viral persistence. Previously we re-
ported that CBP-interacting proteins such as c-Jun and E1A
modulate the function of ORF50 (7). In this study, we showed
that ORF50 represses p53-driven transcriptional activation
FIG. 3. ORF50 represses p53-induced apoptosis. (A) Apoptosis
assays in SAOS2 cells were performed. The hypoploid cell fraction was
analyzed by using a fluorescence-activated cell sorter. PI, propidium
iodide. (B) To verify the results of fluorescence-activated cell sorting,
the level of apoptosis was determined by counting DAPI-stained con-
densed nuclei in GFP-expressing cells by using a fluorescence micro-
scope.
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through a CBP-related mechanism. CBP seems to be a key
molecule in the interaction of ORF50 with transcriptional fac-
tors such as c-Jun, E1A, and p53. An experiment to define the
effects of ORF50 on other CBP-related promoters is under
progress.
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